Skip to main content

Table 4 Changes in laboratory data in patients stratified according to HbA1c at baseline

From: High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: Results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)

  HbA1c <6.5% (n = 86) HbA1c ≥6.5% (n = 40)
  Baseline Follow-up Actual change % change Baseline Follow-up Actual change % change
TC (mg/dl) 214.6 ± 34.5 157.1 ± 20 −57.6 ± 36.9 −25.3 ± 13.9 211.3 ± 35.4 159.3 ± 31.5 −52 ± 34.9 −23.5 ± 15
TG (mg/dl) 145.6 ± 90.3 121 ± 56.2 −24.6 ± 71.1 −8.9 ± 34.7 152.4 ± 75.9 150.4 ± 76.6* −2.0 ± 76.2 4.0 ± 44.6
HDL-C (mg/dl) 47.9 ± 10.7 57.0 ± 11.6 9.2 ± 9.0 21.5 ± 22.3 45.4 ± 11.1 51.3 ± 11 6.0 ± 10.2 16.0 ± 24
LDL-C (mg/dl) 140.4 ± 32.3 81.8 ± 15.7 −58.7 ± 33.1 −39.2 ± 16.6 139.7 ± 30.1 85.3 ± 23.9 −54.4 ± 31.2 −37.3 ± 17.7
VLDL-C (mg/dl) 25.4 ± 16.7 19.6 ± 10.4 −5.8 ± 14.2 −4.1 ± 61.8 26.7 ± 16.9 26.5 ± 15 −0.2 ± 16.9 18.1 ± 76.9
non-HDL-C (mg/dl) 166.7 ± 33.9 100 ± 16.9 −66.7 ± 33.5 −38.2 ± 13.9 166 ± 33.1 108 ± 28.5 −58 ± 33 −33.6 ± 17.0
small dense LDL 0.36 ± 0.04 0.35 ± 0.03 −0.01 ± 0.04 −2.77 ± 10.97 0.36 ± 0.04 0.35 ± 0.03 −0.01 ± 0.05 −2.31 ± 11.48
RLP-C (mg/dl) 5.7 ± 5.6 3.6 ± 1.4 −2.1 ± 5.2 −17.3 ± 38.2 5.7 ± 3.7 4.9 ± 2.9 −0.8 ± 3.9 −4 ± 51.3
LDL-C/HDL-C 3.1 ± 1.0 1.5 ± 0.4 −1.6 ± 0.8 −49.1 ± 14.1 3.2 ± 0.9 1.7 ± 0.5 −1.5 ± 0.9 −44.3 ± 16.8
hs-CRP (ng/ml) 2836 ± 7045 821 ± 1331 −2014 ± 7111 −16.2 ± 104.7 4494 ± 9277 1172 ± 1934 −3322 ± 9158 91.9 ± 489.7
  1. Data are means ± SD.
  2. *p < 0.05 and p < 0.01 vs patients with HbA1c <6.5%.
  3. HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; VLDL-C, VLDL-cholesterol; hs-CRP, high-sensitive C-reactive protein.